NCT01848717Unknown不适用
A Single-Center, Single Arm, Pre-post Test Design, Open Clinical Study to Evaluate the Efficacy and Safety of MINTLIFT® Group for Nasolabial Fold
Chung-Ang University Hosptial, Chung-Ang University College of Medicine1 个研究点 分布在 1 个国家目标入组 62 人开始时间: 2012年11月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 62
- 试验地点
- 1
- 主要终点
- The percentage of the subjects who demonstrated wrinkle improvement to -1 or below in WSRS as determined by an independent evaluator
研究概览
简要总结
The objective of this clinical test is to verify the safety and efficacy of MINTLIFT®, used for the purpose of improving the appearance of the nasolabial fold on both sides of the face.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Individuals who desire an improvement in the appearance of the nasolabial fold on both sides of the face and who have a score of 3 or 4 on the Wrinkle Severity Rating Scale (WSRS) at the time of the screening and at the baseline time point
- •Individuals who have consented to abstain from any other dermatological procedures or treatments, including treatments for wrinkle reduction in the facial area, during the duration of this clinical test
排除标准
- •Subjects who have a scar or hypertrophic scar or a history of keloid conditions that may affect the determination of effect
- •Subjects allergic to local anesthetics or sleep anesthetics
- •Subjects whose ALT/AST ratio is 2.5 times or more greater than the normal upper limit
- •Subjects who have been administered an anticoagulant (with the exception of low dosage aspirin (100mg, up to 300mg/day)) within 2 weeks of the date of the screening, or who require an anticoagulant during the period of the clinical test
- •Subjects who have been administered systemic corticosteroids or anabolic steroids within two weeks of the date of the screening or who require their administration during the period of the clinical test (note, however, that the administration of inhaled corticosteroids in a standardized dosage is permissible)
- •Subjects who have been administered Vitamin E or non-steroidal anti-inflammatory drugs within 1 week of the date of the screening
- •Subjects who have used Topical liniments in the facial area (steroids, retinoids: only medical drugs are included in this criteria, with the exclusion of cosmetic products) within 4 weeks of the date of the screening or who plan on continuing usage during the period of the clinical test
- •Subjects who have received wrinkle reduction treatment using CaHA within 1 year of the date of the screening
- •Subjects who have received wrinkle reduction treatment using collagen or HA filler within 6 months of the date of the screening, or who have received acne treatment, skin regeneration procedures, or cosmetic surgical procedures (including Botox injections) in the facial area
- •Subjects who have a permanent skin expanding implant such as Softform or silicon inserted in the facial area
- •Subjects who have scars in the facial area requiring treatment that has not healed for a period of 1 year or longer, or who have a scar or trace in the area on which the clinical test device will applied.
- •Subjects who have a chronic or recurrent infection or a history of inflammatory disease that may affect this clinical test
- •Subjects who have experienced severe allergies such as symptoms of anaphylaxis
结局指标
主要结局
The percentage of the subjects who demonstrated wrinkle improvement to -1 or below in WSRS as determined by an independent evaluator
时间窗: 12th week of the application of the test device
The percentage of the subjects within the test group who demonstrated wrinkle improvement to -1 or below in WSRS in the 12th week following the application of the device in comparison to the condition prior to the application (12th week- prior to application) as determined by an independent evaluator
次要结局
- The percentage of the subjects who demonstrated wrinkle improvement to -1 or below in WSRS as determined by an independent evaluator(in the 4th, 8th and 24th week following the application of the device)
- The percentage of the subjects who demonstrated wrinkle improvement to -1 or below in WSRS as determined by the investigator(in the 4th, 8th, 12th and 24th week following the application of the device)
- The average of the differences between the baseline and the WSRS evaluated by the independent evaluator(in the 4th, 8th, 12th and 24th week following the application of the test device)
- The average of the differences between the baseline and the WSRS evaluated by the subject(in the 4th, 8th, 12th and 24th week following the application of the test device)
- The average value of Global Aesthetic Improvement Scale (GAIS) scores as determined by the investigator and the distribution of scores(in the 12th and 24th week following the application of the test device)
- The average value of GAIS scores as determined by the subject and the distribution of scores(in the 12th and 24th week following the application of the test device)
研究者
Beom Joon Kim
Associate Professor
Chung-Ang University Hosptial, Chung-Ang University College of Medicine
研究点 (1)
Loading locations...
相似试验
终止
早期 1 期
Study to Evaluate the Safety and Preliminary Efficacy of CLL1 and CD38 Dual CAR-T in r/r AMLAcute Myeloid LeukemiaNCT06110208920th Hospital of Joint Logistics Support Force of People's Liberation Army of China3
已完成
不适用
Rapid Radiation Therapy for Painful Osseous Metastatic DiseaseBone MetastasesNCT01391234University of Virginia28
暂停
早期 1 期
Universal CAR-T Cells (REVO-UWD-00B) for Refractory and Relapsed Multiple MyelomaMultiple MyleomaRefractory and Relapsed Multiple MyelomaNCT06663046Wondercel Biotech (ShenZhen)30
已完成
不适用
The Up-LIFT Study of Non-Invasive ARC Therapy for Spinal Cord InjuryChronic Spinal Cord InjuryNCT04697472ONWARD Medical, Inc.65
已完成
不适用
A Soft Silicone Wound Contact Layer Containing Silver in the Treatment of Skin Grafts in Surgical Burn Patients.Burn InjurySkin GraftNCT02210208Molnlycke Health Care AB25